Clinical trial · Observational
Follow Up of High Risk Hodgkin Lymphoma in First Complete Remission
Impact on Survival of Early Detection of Recurrence in the Follow Up of High Risk Hodgkin Lymphoma in First Complete Remission
NCT04298619CI-TRIAL-00043859HOLYFUcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Cohort study enrolled high-risk Hodgkin Lymphoma patients in first relapse after induction therapy followed after remission either with a systemic imaging-based surveillance (Imaging cohort) or with standard clinical-based surveillance (standard cohort).
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| High Risk | — | UNRESOLVED | — |
| Hodgkin Lymphoma | Hodgkin Lymphoma | ONTOLOGY_EXACT | 0.90 |
| Relapse | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Imaging cohort: integrated imaging follow-up | Diagnostic Test | — | UNRESOLVED |
| Standard cohort: Clinical lab follow-up | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Standard cohort
- description
- Clinical-based surveillance after first complete remission in High risk Hodgkin Lymphoma patients: * symptom assessment * blood tests * physical examination
- interventionNames
- Diagnostic Test: Standard cohort: Clinical lab follow-up
- label
- Imaging cohort
- description
- Clinical-based surveillance after first complete remission in High risk Hodgkin Lymphoma patients: * symptom assessment * blood tests * physical examination * Positron Emission Tomography (PET)/Computed Tomography (CT) or Chest X-Ray ultrasonography scan of superficial, mediastinal, abdominal and pelvic lymph nodes
- interventionNames
- Diagnostic Test: Standard cohort: Clinical lab follow-up
- Diagnostic Test: Imaging cohort: integrated imaging follow-up
Primary outcomes (1)
- measure
- Event Free Survival (EFS)
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * High risk Hodgkin Lymphoma * achievement of complete response to first line therapy Exclusion Criteria: * comorbidities that could impair participation in follow-up procedures
References
Publications (0)
Data not yet available
No reference posted for this study.